NCT05186480 is a NA clinical trial of Neo Mune in Sepsis, sponsored by NewGiza University.

Who is sponsoring NCT05186480?

NCT05186480 is sponsored by NewGiza University.

What drugs are being tested in NCT05186480?

Interventions in NCT05186480: Neo Mune.

What condition does NCT05186480 study?

NCT05186480 studies Sepsis, Critical Illness.

Is NCT05186480 still recruiting?

NCT05186480 is currently status unknown. Last updated 19 January 2022.

Last reviewed 2022-01-19 · How we verify

NCT05186480

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Effect of Immune Modulating Enteral Nutrition Formula

Status unknown NA Last updated 19 January 2022

What this trial tests

NA trial testing Neo Mune in Sepsis in 40 participants. Status unknown.

Timeline

3 October 2021

Primary endpoint
1 March 2022

28 March 2022

Quick facts

Lead sponsor	NewGiza University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	40
Start date	3 October 2021
Primary completion	1 March 2022
Estimated completion	28 March 2022
Sites	1 location across Egypt

Drugs / interventions tested

Neo Mune

Conditions studied

Sepsis — all drugs for Sepsis →
Critical Illness — all drugs for Critical Illness →

Sponsor

NewGiza University

Who can join

18 and older, any sex, with Sepsis or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim is to compare the efficacy and tolerability of an immune modulating enteral nutrition formula versus the regular formula on the outcomes of critically ill septic patients by assessment of clinical outcomes, immune profile, tolerability and enteral nutrition intolerance and laboratory markers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other NewGiza University trials

Trials by the same sponsor.

NCT07180732 — Accuracy of Injection Moulding Technique · NA · completed
NCT06689202 — Assessment of Oral Health Knowledge, Attitude and Behavior of Adult Patients in Egypt · completed
NCT06601972 — Partial Caries Removal in Permanent Molars Restored Using Giomer · NA · not yet recruiting
NCT06562699 — Buffering Capacity of Matcha Green Tea on Salivary PH After an Acidic Attack · NA · not yet recruiting
NCT05135013 — The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05186480 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NewGiza University
Last refreshed: 19 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05186480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing